BriaCell Therapeutics Corp. Warrant expiring 2031

BriaCell Therapeutics Corp. is a pre-clinical stage immuno-oncology company developing targeted immunotherapies for cancer. Its lead candidate, Bria-IMT, is a targeted immunotherapy for end-stage breast cancer in Phase 3 trials. The company also develops Bria-OTS, a personalized off-the-shelf immunotherapy, and a soluble CD80 protein therapeutic that stimulates the immune system and acts as an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County, and a collaboration with MSK Accelerator. The company is headquartered in West Vancouver, Canada.